<SEC-DOCUMENT>0001171843-12-003646.txt : 20121016
<SEC-HEADER>0001171843-12-003646.hdr.sgml : 20121016
<ACCEPTANCE-DATETIME>20121016080521
ACCESSION NUMBER:		0001171843-12-003646
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20121016
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20121016
DATE AS OF CHANGE:		20121016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			THERAVANCE INC
		CENTRAL INDEX KEY:			0001080014
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943265960
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30319
		FILM NUMBER:		121145039

	BUSINESS ADDRESS:	
		STREET 1:		901 GATEWAY BLVD
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		6508086000

	MAIL ADDRESS:	
		STREET 1:		901 GATEWAY BLVD
		CITY:			S. SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED MEDICINE INC
		DATE OF NAME CHANGE:	20000302
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>document.htm
<DESCRIPTION>FORM 8-K FILING DOCUMENT
<TEXT>
<html>

	<head>
		<title>Form 8-K Filing</title>
	</head>

	<body>
		<p align="center"><b>UNITED STATES</b><br>
			<b>SECURITIES AND EXCHANGE COMMISSION</b><br>
			<b>Washington, D.C. 20549</b><br>
		</p>
		<p align="center"><b>FORM 8-K</b></p>
		<p align="center"><font size="2"><b>Current Report Pursuant<br>
					to Section 13 or 15(d) of the<br>
					Securities Exchange Act of 1934</b></font></p>
		<p align="center"><font size="2">Date of Report (Date of earliest event Reported): October 16, 2012</font></p>
		<p align="center"><font size="4"><b>THERAVANCE, INC.</b></font><br>
			<font size="2">(Exact Name of Registrant as Specified in its Charter)</font></p>
		<!-- Registrant's State of Inc, File and IRS Number -->
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td width="32%" align="center"><font size="2"><b>Delaware</b></font></td>
				<td width="3%"><font size="2">&nbsp;</font></td>
				<td width="32%" align="center"><font size="2"><b>000-30319</b></font></td>
				<td width="3%"><font size="2">&nbsp;</font></td>
				<td width="32%" align="center"><font size="2"><b>94-3265960</b></font></td>
			</tr>
			<tr valign="top">
				<td width="32%" align="center"><font size="2">(State or Other Jurisdiction of Incorporation) </font></td>
				<td width="3%"><font size="2">&nbsp;</font></td>
				<td width="32%" align="center"><font size="2">(Commission File Number) </font></td>
				<td width="3%"><font size="2">&nbsp;</font></td>
				<td width="32%" align="center"><font size="2">(I.R.S. Employer Identification Number) </font></td>
			</tr>
		</table>
		<!-- Registrant's Postal Addess and Zip Code --><br>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="bottom">
				<td width="47%" align="center"><font size="2"><b>901 Gateway Boulevard<br>
South San Francisco, California 94080 <br>
					(650) 808-6000</b></font></td>
			</tr>
			<tr valign="top">
				<td width="47%" align="center"><font size="2">(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)</font></td>
			</tr>
		</table>
		<p align="center"><br>
			<!--<font size="2"><b>________________________________________________________________________________</b><br>
			(Former name or former address, if changed since last report)</font><font size="2"><b></b></font>--></p>
		<!-- Simultaneous filing obligation checkboxes --><br>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td colspan="3"><font size="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):<br>
						<br>
					</font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></td>
			</tr>
			<tr valign="top">
				<td width="21"><font size="2">&nbsp;</font></td>
				<td width="40"><font size="2">[ &nbsp;&nbsp;]</font></td>
				<td nowrap><font size="2">&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></td>
			</tr>
		</table>
		<br>
		<hr noshade="1">
		<font size="2"></font>
		<p><b><p><font size="3"><b>Item 8.01. Other Events.</b></font></p></b></p>
		<p><font size="2"><p>
	On October 16, 2012, Theravance, Inc. (the &quot;Company&quot;) issued a press release announcing that the Company signed a collaboration agreement with Merck, known as MSD outside the United States and Canada, to discover, develop and commercialize novel small molecule therapeutics directed towards a target being investigated for the treatment of hypertension and heart failure. In exchange for granting Merck a worldwide, exclusive license to the Company&#39;s therapeutic candidates, Theravance will receive a $5 million upfront payment, funding for research, and be eligible for milestone payments totaling up to $148 million for the first indication and royalties on worldwide annual net sales of any products derived from the collaboration. Theravance will be responsible for discovery and Merck will be responsible for and fund all development and commercialization activities. The initial research term is twelve months, with optional extensions by mutual agreement, and Merck can terminate the agreement at any time. A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated herein by reference.</p>
</font></p>
		<font size="2"></font>
		<p><b><p><font size="3"><b>Item 9.01. Financial Statements and Exhibits.</b></font></p></b></p>
		<p><font size="2"><p>
	<font size="2"> </font></p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">

		<tr>
			<td valign="top" width="4%">
				<font style ="font-size: 12px">(d)</font></td>
			<td valign="top">
				<font style ="font-size: 12px">Exhibits.</font></td>
		</tr>

</table>
<p>
	 </p>
<table border="0" cellpadding="0" cellspacing="0" width="84%">

		<tr>
			<td valign="bottom" width="27%">
				<p>
					<font style="font-size: 12px"><b><u>Exhibit</u></b></font></p>
			</td>
			<td valign="bottom" width="1%">
				<p>
					 </p>
			</td>
			<td valign="bottom">
				<p>
					<font style="font-size: 12px"><b><u>Description</u></b></font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="27%">
				<p>
					<font style="font-size: 12px">Exhibit 99.1</font></p>
			</td>
			<td valign="bottom" width="1%">
				<p>
					 </p>
			</td>
			<td valign="bottom">
				<p>
					<font style="font-size: 12px">Press Release of Theravance, Inc. dated October 16, 2012</font></p>
			</td>
		</tr>

</table>
<p>
	<font style="font-size: 12px"><br />
	</font></p>
</font></p>
		<hr noshade="1">
		<!-- Registrant's Signature -->
		<p align="center"><b><font size="2">SIGNATURE</font></b></p>
		<p><font size="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>
		<table cellpadding="0" border="0" width="100%" cellspacing="0">
			<tr valign="top">
				<td width="47%"><font size="2">&nbsp;</font></td>
				<td width="5%"><font size="2">&nbsp;</font></td>
				<td style="text-transform: uppercase" width="47%"><font size="2"><b>THERAVANCE, INC.</b><br>
					<br>
					</font></td>
			</tr>
			<tr valign="top">
				<td width="47%">
					<p><font size="2">Date: October 16, 2012</font></p>
				</td>
				<td width="5%"><font size="2">&nbsp;</font></td>
				<td width="47%"><font size="2"><b><u>/s/<!--MICHAEL W. AGUIAR--> Michael W. Aguiar</u></b><br>
					Michael W. Aguiar<br>
					Chief Financial Officer</font></td>
			</tr>
		</table>
		<font size="2"><hr noshade="noshade" />
<p align="center">
	<b><br />
	EXHIBIT INDEX</b></p>
<p align="center">
	 </p>
<p align="center">
	 </p>
<table border="0" cellpadding="0" cellspacing="0" width="84%">

		<tr>
			<td valign="bottom" width="27%">
				<p>
					<font style="font-size: 12px"><b><u>Exhibit</u></b></font></p>
			</td>
			<td valign="bottom" width="1%">
				<p>
					<font style="font-size: 12px"><br />
					</font></p>
			</td>
			<td valign="bottom">
				<p>
					<font style="font-size: 12px"><b><u>Description</u></b></font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="27%">
				<p>
					<font style="font-size: 12px">Exhibit 99.1</font></p>
			</td>
			<td valign="bottom" width="1%">
				<p>
					 </p>
			</td>
			<td valign="bottom">
				<p>
					<font style="font-size: 12px">Press Release of Theravance, Inc. dated October 16, 2012</font></p>
			</td>
		</tr>

</table>
</font>
	</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>newsrelease.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>Theravance and Merck Sign Cardiovascular Disease Collaboration</title></head><body><p align="right">EXHIBIT 99.1</p><h3 align="center">Theravance and Merck Sign Cardiovascular Disease Collaboration</h3><p>SOUTH SAN FRANCISCO, Calif., Oct. 16, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) announced today that it has signed a collaboration agreement with Merck, known as MSD outside the United States and Canada, to discover, develop and commercialize novel small molecule therapeutics directed towards a target being investigated for the treatment of hypertension and heart failure.</p><p>
	In exchange for granting Merck a worldwide, exclusive license to its therapeutic candidates, Theravance will receive a $5 million upfront payment, funding for research, and be eligible for milestone payments totaling up to $148 million for the first indication and royalties on worldwide net sales of any products derived from the collaboration.</p><p>
	"Despite years of medical advances, there remain significant unmet medical needs in the management of cardiovascular disease," said Mathai Mammen, M.D., Ph.D., Senior Vice President of Research and Early Clinical Development at Theravance. "Over the last several years, Theravance has gained significant insights into the design of novel molecules directed towards certain cardiovascular targets. We are pleased to be working with Merck, an industry leader in the development of innovative cardiovascular medicines, to bring new therapies to patients."</p><p>
	"Merck remains committed to the discovery and development of new therapies for cardiovascular disease," said Michael Mendelsohn, M.D., Senior Vice President, Cardiovascular Research at Merck. "By combining Merck's experience with the strengths of the Theravance team we are well positioned to advance this new collaboration forward."</p><p>
	<strong>About Cardiovascular Disease</strong></p><p>
	Cardiovascular disease (CVD) encompasses diseases, such as hypertension and heart failure, in which changes in the heart and blood vessels are associated with morbidity and mortality.&#160;Collectively, CVD is the leading cause of death and disability in the world.</p><p>
	<strong>About Theravance</strong></p><p>
	Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Theravance's key programs include: Relvar&#8482; or Breo&#8482; (FF/VI), umeclidinium bromide/vilanterol (UMEC/VI) and MABA (Bifunctional Muscarinic Antagonist-Beta<sub>2</sub> Agonist), each partnered with GlaxoSmithKline&#160;plc, and its oral Peripheral Mu Opioid Receptor Antagonist program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit Theravance's web site at www.theravance.com.</p><p>
	THERAVANCE&#174;, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE&#174; are registered trademarks of Theravance, Inc.</p><p>
	Relvar&#8482; or Breo&#8482; (FF/VI) is an investigational medicine and is not currently approved anywhere in the world. Relvar&#8482; and Breo&#8482; are trademarks of the GlaxoSmithKline group of companies. The use of these brand names has not yet been approved by any regulatory authority.</p><p>
	<strong>Theravance Forward-Looking Statements</strong></p><p>
	This press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Theravance intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements regarding the potential benefits and mechanisms of action of drug candidates, statements concerning enabling capabilities of Theravance's approach to drug discovery and its proprietary insights, statements concerning expectations for the discovery, development and commercialization of product candidates &#160;and projections of revenue, expenses and other financial items. These statements are based on the current estimates and assumptions of the management of Theravance as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance to be materially different from those reflected in its forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to delays or difficulties in commencing or completing clinical and non-clinical studies, the potential that results of clinical or non-clinical studies indicate product candidates are unsafe or ineffective, our dependence on third parties in the conduct of our clinical studies, delays or failure to achieve regulatory approvals for product candidates and risks of collaborating with third parties to discover, develop and commercialize products. These and other risks are described in greater detail under the heading "Risk Factors" contained in Theravance's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 1, 2012 and the risks discussed in our other period filings with SEC. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance assumes no obligation to update its forward-looking statements.</p><p>
	<strong>Theravance Contact Information: <br>
	</strong>Michael W. Aguiar&#160;<br>
	Senior Vice President and Chief Financial Officer<br>
	650-808-4100&#160;<br>
	investor.relations@theravance.com&#160;&#160;</p></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
